Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.490 -0.040 (-2.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

November 20, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

November 20, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 20, 2025

Via Benzinga

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

November 20, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

November 14, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

August 19, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 18, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

August 18, 2025

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 18, 2025

Via Benzinga

Inhibikase Posts Wider Loss in Q2 ↗

August 14, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 27, 2025

Via Benzinga

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

May 14, 2025

Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

April 14, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

March 27, 2025

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Announces Expansion of Senior Leadership Team

February 24, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

February 18, 2025

From Inhibikase Therapeutics

Via GlobeNewswire

This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

February 12, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 30, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

January 29, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

November 14, 2024

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 08, 2024

Via Benzinga

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 08, 2024

Via Benzinga

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗

October 24, 2024

Via Benzinga

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

October 21, 2024

From Inhibikase Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 14, 2024

Via Benzinga

Dow Surges 350 Points; US Crude Oil Stocks Increase ↗

October 09, 2024

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 09, 2024

Via Benzinga

Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August ↗

October 09, 2024

Via Benzinga

Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today ↗

October 09, 2024

Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.